Free Trial
NASDAQ:PGEN

Precigen (PGEN) Stock Price, News & Analysis

Precigen logo
$1.83 -0.08 (-4.19%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.82 -0.01 (-0.27%)
As of 07/11/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Precigen Stock (NASDAQ:PGEN)

Key Stats

Today's Range
$1.81
$1.92
50-Day Range
$1.28
$1.91
52-Week Range
$0.65
$2.17
Volume
1.35 million shs
Average Volume
1.47 million shs
Market Capitalization
$540.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

Precigen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

PGEN MarketRank™: 

Precigen scored higher than 82% of companies evaluated by MarketBeat, and ranked 203rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Precigen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Precigen has only been the subject of 2 research reports in the past 90 days.

  • Read more about Precigen's stock forecast and price target.
  • Earnings Growth

    Earnings for Precigen are expected to grow in the coming year, from ($0.32) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Precigen is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Precigen is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Precigen has a P/B Ratio of 14.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Precigen's valuation and earnings.
  • Percentage of Shares Shorted

    19.85% of the float of Precigen has been sold short.
  • Short Interest Ratio / Days to Cover

    Precigen has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Precigen has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Precigen does not currently pay a dividend.

  • Dividend Growth

    Precigen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.85% of the float of Precigen has been sold short.
  • Short Interest Ratio / Days to Cover

    Precigen has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Precigen has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Precigen has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Precigen this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for PGEN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Precigen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    47.10% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 33.51% of the stock of Precigen is held by institutions.

  • Read more about Precigen's insider trading history.
Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

PGEN Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Precigen Announces Key Approvals at Annual Meeting
J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)
See More Headlines

PGEN Stock Analysis - Frequently Asked Questions

Precigen's stock was trading at $1.12 at the beginning of the year. Since then, PGEN shares have increased by 63.4% and is now trading at $1.83.

Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The biotechnology company had revenue of $1.34 million for the quarter, compared to analyst estimates of $0.50 million. Precigen had a negative net margin of 3,728.87% and a negative trailing twelve-month return on equity of 279.20%.

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Nordic American Tankers (NAT), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Hess (HES) and Boeing (BA).

Company Calendar

Last Earnings
5/14/2025
Today
7/12/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PGEN
CIK
1356090
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+227.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$126.24 million
Net Margins
-3,728.87%
Pretax Margin
-3,770.86%
Return on Equity
-279.20%
Return on Assets
-79.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.53
Quick Ratio
3.53

Sales & Book Value

Annual Sales
$3.92 million
Price / Sales
137.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.13 per share
Price / Book
14.08

Miscellaneous

Outstanding Shares
295,180,000
Free Float
156,150,000
Market Cap
$540.18 million
Optionable
Optionable
Beta
1.78

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:PGEN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners